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Abstract
Introduction: Adiponectin and sex hormone binding globulin (SHBG) play a role in glucose metabolism. Hyperthyroidism has an impact 
on carbohydrate metabolism and could affect insulin resistance. The aim of this study was to assess the associations between insulin resis-
tance, adiponectin and SHBG among hyperthyroid Graves` disease (GD) women.
Material and methods: The study was undertaken in 60 women with hyperthyroidism in the course of GD; 32 healthy women matched 
by BMI and age formed the control group. The concentrations of: free thyroxine (fT4), free triiodothyronine (fT3), thyroid-stimulating 
hormone (TSH), SHBG, insulin, adiponectin and glucose were measured, and the homeostasis model assessment (HOMA-I) was calculated. 
Results: Compared to euthyroid subjects, hyperthyroid GD women had elevated glucose, fT4, fT3, adiponectin and SHBG concentra-
tions, but there were no differences in HOMA-I. When we explored the relations between adiponectin as well as SHBG with glucose and 
HOMA-I, we observed that HOMA-I was associated with adiponectin and SHBG only in the control group, and in hyperthyroidism there 
were no such connections. We found positive associations between adiponectin, SHBG, fT4 and fT3 in the GD group. 
Conclusions: Elevated concentrations of adiponectin and SHBG were observed in hyperthyroidism but they were not related to insulin 
resistance. (Endokrynol Pol 2013; 64 (1): 26–29)
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Streszczenie
Wstęp: Adiponektyna i białko wiążące hormony płciowe (SHBG) odgrywają rolę w metabolizmie glukozy. W nadczynności tarczycy 
często występują zaburzenia gospodarki węglowodanowej i oporność insulinowa. Celem pracy była próba oceny powiązań pomiędzy 
adiponektyną, SHBG i opornością insulinową u kobiet z nadczynnością tarczycy w przebiegu choroby Gravesa. 
Materiał i metody: Badanie przeprowadzono wśród 60 kobiet z nadczynnością tarczycy w przebiegu choroby Gravesa. 32 zdrowe kobiety 
stanowiły grupę kontrolną. Grupy nie różniły się między sobą pod względem wieku i BMI. Oceniano stężenie: wolnej tyroksyny (fT4), 
wolnej trijodotyroniny (fT3), TSH, SHBG, insuliny, adiponektyny i glukozy. Oporność insulinową oceniano jako wskaźnik HOMA-I. 
Wyniki: Porównując z grupą kontrolną, kobiety z nadczynnością miały wyższe stężenie fT4, fT3, SHBG, adiponektyny, glukozy, natomiast 
nie stwierdzono różnic we wskaźniku HOMA-I. Gdy oceniano powiązania pomiędzy adiponektyną, SHBG oraz HOMA-I i glukozą, stwier-
dzono korelacje tylko w grupie kontrolnej, natomiast w grupie badanej te zależności nie występowały. Wykryto powiązania pomiędzy 
adiponektyną, SHBG, fT4 i fT3 w grupie kobiet z tyreotoksykozą. 
Wnioski: W nadczynności tarczycy występują podwyższone stężenia adiponektyny i SHBG, ale nie wpływa to na rozwój oporności 
insulinowej. (Endokrynol Pol 2013; 64 (1): 26–29)
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Introduction
Impaired fasting glucose and impaired glucose toler-
ance often develop in hyperthyroidism. In patients with 
diabetes, the progress of diabetes is usually worsening 
and unstable, due to a variety of mechanisms. Thyroid 
hormones act antagonistically to insulin, mainly within 
the liver level. Gluconeogenesis and glycogenolysis in-
crease. The expression of glucose transporter 2 (GLUT-2) 
in the hepatocytes and the cellular glucose transport 
intensifies. In the digestive tract, glucose resorption 
increases, secondary to the intensified expression of the 
sodium/glucose transporter that is located on the surface 
of the enterocytes. At the same time, in the course of 
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hormone sensitive lipase (HSL) dependent lipolysis, 
substantial quantities of free fatty acids are released 
in adipose tissue, which may contribute to the develo-
pment of peripheral insulin resistance [1]. Elevated 
homeostasis model assessment of insulin resistance 
index (HOMA-I) has been reported in hyperthyroid-
ism in some [2] but not in all studies [3]. The excess 
of thyroid hormones significantly affects adipocyte 
function, mainly lipoprotein metabolism, as well as 
adipocytokines secretion [4, 5]. Reduced adiponectin 
serum level has been shown to be a sensitive indicator 
of insulin resistance [6, 7]. However, several researchers 
have described a higher concentration of adiponectin 
in the hyperthyroid stage compared to healthy persons 
[5, 8, 9]. Another marker linked to insulin resistance is 
the concentration of the sex hormone binding globulin 
(SHBG) [10]. Insulin resistance is connected to a reduced 
concentration of SHBG [10], but in hyperthyroidism the 
secretion of SHBG increases [11]. The contribution of 
adiponectin and SHBG in the pathogenesis of deregula-
tions in the carbohydrate metabolism in the course of 
hyperthyroidism is not known. 
The aim of this study was to attempt to evaluate the 
connections between insulin resistance and SHBG as 
well as adiponectin in hyperthyroidism.
Material and methods
The study was undertaken in 60 women with hyper-
thyroidism in the course of Graves` disease (GD); 
32 healthy women formed the control group. The 
groups did not differ in terms of age and body mass 
index (BMI). GD was diagnosed on the basis of typical 
clinical picture, ultrasonographic image, and increased 
level of TSH receptor antibodies (TRAb) and thyroid 
peroxidase antibodies (TPO-Abs). The patients were 
evaluated at the time of diagnosis. The concentrations of 
free thyroid hormones, i.e. free thyroxine (fT4), free trii-
odothyronine (fT3) and thyroid-stimulating hormone 
(TSH) were estimated by the radioimmunology method 
(ZenTech S.A.). The concentrations of SHBG and insulin 
were measured using RIA commercial kits (DSL), adi-
ponectin was measured by RIA (Linco Research), and 
glucose with the use of Roche Diagnostic reagent. The 
insulin resistance index assessed by the homeostasis 
model assessment was calculated using the formula: 
HOMA-I = concentration of glucose in blood serum 
(mg/dL)/ 18.1 × concentration of insulin (ulU/mL)/22.5 [12]. 
The study was approved by the Bioethics Committee 
of the Medical University of Silesia.
Results
The concentrations of free hormones were significantly 
higher, and the concentration of TSH lower, in hyper-
thyroidism than in the control group. The glucose con-
centration was higher in patients with GD compared 
to the control group, but there weren’t any differences 
between the groups in terms of HOMA-I (Table I). In this 
study we observed significantly higher concentrations 
of adiponectin and SHBG in the hyperthyroid group 
compared to the control group (Table I). We showed 
a significant relationship between the concentration of 
adiponectin and fT4, as well as between adiponectin and 
Table I. Clinical and biochemical characteristics of the hyperthyroid and control groups, *p < 0.001 tested v. control group
Tabela I. Porównanie parametrów klinicznych i biochemicznych pomiędzy grupą z nadczynnością tarczycy i grupą kontrolną, 
*p < 0.001 grupa badana v. grupa kontrolna
                                                                                        Hyperthyroid group                                         Control group
Number 60 32
Age (years) 45.8 ± 7.7 49.2 ± 7.3
BMI [kg/m2] 24.6 ± 2.6 24.7 ± 2.6
Glucose [mg/dL] 91.3 ± 4.6* 87.0 ± 5.6
Adiponectin [ug/mL] 20.16 ± 5.94* 14.91 ± 4.95
SHBG [nmol/L] 115.7 ± 35.9* 86.4 ± 22.5
HOMA-I 1.4 (0.9; 1.5) 1.2 [0.8; 1.6]
TSH [mIU/mL] 0.01 ± 0.02* 1.48 ± 0.85
fT4 [ng/dL] 2.53 ± 0.54* 1.13 ± 0.32
fT3 [pg/mL] 7.13 ± 3.25* 2.55 ± 1.21
Normally distributed data is given as mean SD. Skewed data is given as median plus [25;75] percentiles. The significance tests used are the Mann-Whitney 
test for normally distributed variables, and unpaired t test for normally distributed variables
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fT3 in the hyperthyroid group. We also found positive 
correlations between the concentrations of SHBG and 
the concentrations of fT3 and fT4 in the hyperthyroid-
ism group (Table II). These correlations were not present 
in the control group. 
In both the hyperthyroid and control groups, adi-
ponectin correlated positively with SHBG concentra-
tions. HOMA-I was connected with BMI, SHBG and 
adiponectin only in healthy women but not in hyper-
thyroid Graves patients. 
Discussion
Hyperthyroidism has an impact on carbohydrate 
metabolism and could affect insulin resistance. The 
implicated mechanisms are complex and in part unclear. 
Hyperglycaemia results from increased carbohydrate 
absorption, increased gluconeogenesis, and reduced 
hepatic glycogen synthesis. Hyperthyroidism can also 
cause a decrease in tissue reactivity for physiological in-
sulin level, which leads to glucose and lipid metabolism 
dysregulation. Resistance at the molecular level is due 
to defects of the insulin induced stimulation cascade 
[13]. In this study, we observed increased fasting glu-
cose in hyperthyroid patients, but when we evaluated 
insulin resistance by HOMA-I, which we determined 
on the basis of glucose and insulin concentration, we 
did not found any differences between hyperthyroid 
women compared to a control group. However, hy-
perthyroidism can lead to a reduction of BMI which 
promotes insulin sensitivity. Therefore insulin resistance 
is mediated by different confusing factors. 
Adipose tissue releases a number of bioactive 
adipokines such as adiponectin. Serum adiponectin 
is inversely related to the adipose mass and intensi-
fies insulin sensitivity. Researchers have proved that 
low adiponectin levels determine the grade of insulin 
resistance independent from fat tissue mass [7]. The 
globulin directly corrects the insulin signal transfer and 
reduces the glucose concentration without influencing 
insulin secretion. In skeletal muscles, through AMP 
kinase it intensifies the expression of GLUT-4 and the 
glucose uptake. Under the influence of adiponectin, 
the activity of enzymes responsible for gluconeogenesis 
decreases [6].
Excess of thyroid hormones in hyperthyroidism 
leads to lipolysis, a reduction of fat mass, and weight 
loss. Since adipose tissue is reduced in hyperthyroid 
subjects, secretion of adiponectin could be dysregulated. 
Little is known about adiponectin production in hyper-
thyroidism and the limited information about this issue 
is demonstrated by different results. In human studies, 
the excess of thyroid hormones have been connected 
with similar [4, 14] or elevated serum adiponectin levels 
[5, 8, 9]. In the study by Hsieh et al., the treatment of 
thyrotoxicosis was followed by a significant decline of 
serum adiponectin [15]. In the present study, higher 
levels of adiponectin were found in hyperthyroid GD 
women compared to the control group and adiponectin 
was not correlated with HOMA-I in hyperthyroidism. 
This finding does not support a role of adiponectin 
as a factor mediated in disturbances in carbohydrate 
metabolism in thyrotoxicosis. 
The mechanism that binds the adiponectin produc-
tion in respect of the hyperfunction severity grade is 
not known. In our study, adiponectin concentrations 
correlated positively with the concentrations of free 
thyroid hormones, which is compatible with reports by 
other researchers [5, 8, 9, 15]. It is possible that elevated 
adiponectin levels might be a result of thyroid hormones 
stimulation on peroxisome proliferator activated recep-
tor (PPAR) and sterol-regulatory-element-binding pro-
tein (SREBP) signaling [16, 17]. Adiponectin is produced 
by small, differentiating fat cells, and the adiponectin 
gene expression during the preadipocyte maturation 
increases by as much as 100 times. The transcription 
factors: SREBP-1c, CCAAT/enhancer-binding protein (C/
EBP), and PPAR stimulate adiponectin gene expression 
[16]. The secretion also intensifies under the influence 
of insulin, which stimulates SREBP-1c. In hyperthyroid 
subjects, increased secretion of insulin has been dem-
onstrated [1]. Glucocorticosteroids, catecholamines and 
inflammatory cytokines, such as interleukin-6 (IL-6) and 
tumour necrosis factor-alpha (TNF-alpha), are inhibit-
ing factors [18]. PPAR gamma plays the main role in 
inducing the adiponectin gene, and the nuclear factor 
Table II. Spearman`s coefficients of the relationships between biochemical parameters in the hyperthyroid group
Tabela II. Współczynniki korelacji R Spearmana pomiędzy ocenianymi parametrami w grupie badanej
Adiponectin and fT4 R Spearman = 0.33, p < 0.001
Adiponectin and fT3 R Spearman = 0.28, p < 0.001
Adiponectin and SHBG R Spearman = 0.33, p < 0.01
SHBG and fT4 R Spearman = 0.35, p < 0.001
SHBG and fT3 R Spearman = 0.30, p < 0.001
29
Endokrynologia Polska 2013; 64 (1)
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
agonists increase adiponectin blood concentration [19]. 
PPAR binds with the retinoid X receptor (RXR), and 
the formed dimer binds to DNA within the region of 
adiponectin gene promoter (PPRE, PPAR response ele-
ment), which leads to gene activation [16]. 
Furthermore, in the present study, adiponectin cor-
related positively with SHBG. The connections were 
independent from BMI and thyroid function. Those 
relations have been seen before [20, 21], although their 
nature is not known. Gannage-Yares et al. suggested 
that adiponectin could be connected to the production 
of SHBG through hepatocytes [22]. SHBG is a glycopro-
tein coded by a gene located on chromosome 17. It is 
produced by hepatocytes under the control of different 
endocrine and metabolic factors. Oestradiol stimulates 
its synthesis, but insulin and testosterone inhibits it [23]. 
GH and somatomedin are important negative deter-
minants of SHBG levels, and thyroid hormones have 
a strongly positive effect on the production of SHBG. 
Increased production of SHBG in hyperthyroidism 
has been seen previously [11], and was confirmed in 
our study. We also observed the positive correlations 
between SHBG and thyroid hormones. Selva et al. have 
demonstrated that thyroid hormones increase hepatic 
SHBG production by increasing expression of hepato-
cyte nuclear factor-4 alpha (HNF 4-a) [24]. 
Until recently, it has been believed that SHBG syn-
thesis in the liver was directly regulated by insulinae-
mia. However, Selva et al. have questioned the pivotal 
role of insulin, and suggested that the increase of HNF 
4- expression leads to higher SHBG production [25]. 
The important factor affected SHBG serum levels 
is insulin resistance. Low serum SHBG concentrations 
have been shown to predict the occurrence of insulin 
resistance in women [26]. However, in this study we did 
not observe relationships between SHBG concentra-
tions and HOMA-I levels among hyperthyroid women. 
These observations suggest that insulin sensitivity is not 
mediated by SHBG in the hyperthyroid stage. 
Conclusions
There are no relationships between insulin resistance, 
SHBG and adiponectin in hyperthyroidism. Elevated 
SHBG and adiponectin concentrations reflect the degree 
of thyroid hyperfunction.
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